Franklin Resources’s Recursion Pharmaceuticals RXRX Stock Holding History

Franklin Resources’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$767K	Buy	209,039 +171,123	+451%	+$570K	﹤0.01%	2398
2026 Q1	$116K	Buy	37,916 +7,525	+25%	+$29.1K	﹤0.01%	2898
2025 Q4	$124K	Sell	30,391 -65,755	-68%	-$326K	﹤0.01%	2874
2025 Q3	$469K	Buy	96,146 +12,685	+15%	+$66.6K	﹤0.01%	2457
2025 Q2	$422K	Buy	83,461 +152	+0.2%	+$747	﹤0.01%	2399
2025 Q1	$441K	Buy	83,309 +7,530	+10%	+$54.9K	﹤0.01%	2317
2024 Q4	$512K	Buy	75,779 +56,816	+300%	+$382K	﹤0.01%	2280
2024 Q3	$127K	Buy	18,963 +7,027	+59%	+$50.4K	﹤0.01%	2724
2024 Q2	$89.5K	Buy	+11,936	New	+$104K	﹤0.01%	2688

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Franklin Resources's RXRX Position: Q2 2026 in Review

Franklin Resources increased its Recursion Pharmaceuticals (RXRX) stake by 451% in Q2 2026, buying an estimated $570K and bringing the position to 209,039 shares worth $767K. The position accounts for ﹤0.01% of the portfolio, ranked #2398.

Franklin Resources first reported a position in RXRX in Q2 2024 and has held it in 9 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Franklin Resources held 209,039 shares of Recursion Pharmaceuticals worth $767K as of Q2 2026.
Franklin Resources bought 171,123 Recursion Pharmaceuticals shares in Q2 2026, an estimated $570K.
Recursion Pharmaceuticals made up ﹤0.01% of Franklin Resources's portfolio in Q2 2026, its #2398 holding.
Franklin Resources first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Franklin Resources's 13F filing for Q2 2026, filed 13 Aug 2026.